Gerresheimer AG has had a successful second quarter, en route to meeting all of its targets for 2019, Dietmar Siemssen, the CEO, has said in a press release Tursday.
He said that Sensile Medical’s micro pump for Parkinson’s treatment is successfully in use in the European market and is progressing positively. The groundwork is also now being laid in a highly promising new project for the treatment of heart failure, Siemssen noted.
According to the company’s press release, Gerresheimer increased revenues by 7.2% to €356.5m in the second quarter of the financial year 2019, up from €332.6m in the prior-year quarter. The company said the syringe business performed well in the second quarter of 2019.
Revenues with plastic primary pharmaceutical packaging also grew. The medical plastic systems business was stable. Moulded glass primary packaging revenues increased, mainly due to a rise in demand from cosmetics customers. The injection vial, ampoule and cartridge business did particularly well in Europe and Asia, the company said in the press release.
Net income in the second quarter of 2019 was €47.1m, compared to €19.3m in the prior-year quarter. Adjusted net income after non-controlling interests amounted to €58.7m, compared to a prior-year figure of €26.0m. Gerresheimer said that the figure for the second quarter of 2019 was influenced by the positive effect from the derecognition of contingent purchase price components.